Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Establishment of Real-Time Multispectral Imaging for the Detection of Bladder Cancer Using a Preclinical in Vivo Model

Establishment of Real-Time Multispectral Imaging for the Detection of Bladder Cancer Using a... BACKGROUND:Emerging imaging technologies such as real-time multispectral imaging (rMSI) hold great potential for simultaneous visualization of multiple target structures using fluorophores on various tumours including bladder cancer (BC). These technologies, however, require a multi-step preclinical evaluation process, including mouse models.OBJECTIVE:To demonstrate the suitability of the new rMSI technology for the detection of premalignant lesions and malignant BC in a preclinical mouse model using contrast agents.METHODS:Tumours were induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN), which is known to induce BC in rodent models. In total, 30 mice (C57BL/6) were fed with 0.1% BBN ad libitum in drinking water for up to 5 months. Bladders were excised at 3 (n = 6) and 5 months (n = 24) of treatment and incubated ex vivo with Hexaminolevulinat (HAL, Hexvix®), CD47-FITC, CD90.2-FITC or a combination of CD90.2-FITC/CD47-FITC and HAL. The bladders were analyzed by an endoscopic rMSI prototype system equipped with a spectral filter (Chroma), a 4 mm endoscope (Karl Storz) with 30° optic, a LED light source and a PC with a microcontroller board.RESULTS:5-month treatment of mice with 0.1% BBN led to the formation of squamous carcinoma (46%, n = 11) while urothelial carcinoma was observed only in one mouse (4%, n = 1). Carcinoma in situ (CIS) was detectable in twelve out of twenty-four mice (50%, n = 12) treated for 5 month and in three out of six mice (50%, n = 3) treated for 3 months.The metabolite of HAL, protoporphyrin IX (PpIX), could be reliably and specifically detected in all of mouse bladder tumours and CIS. However, detection of the CD90.2 surface marker was less reliable, potentially due to species- or tumour-subtype specificity.CONCLUSIONS:This model offers the potential for preclinical imaging studies with combined fluorescence targets, e.g. HAL, in combination with BC-specific antibodies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bladder Cancer IOS Press

Establishment of Real-Time Multispectral Imaging for the Detection of Bladder Cancer Using a Preclinical in Vivo Model

Download PDF
10 pages

Loading next page...
 
/lp/ios-press/establishment-of-real-time-multispectral-imaging-for-the-detection-of-LioVz5U8b2

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 2020 © 2020 – IOS Press and the authors. All rights reserved
ISSN
2352-3727
eISSN
2352-3735
DOI
10.3233/BLC-200314
Publisher site
See Article on Publisher Site

Abstract

BACKGROUND:Emerging imaging technologies such as real-time multispectral imaging (rMSI) hold great potential for simultaneous visualization of multiple target structures using fluorophores on various tumours including bladder cancer (BC). These technologies, however, require a multi-step preclinical evaluation process, including mouse models.OBJECTIVE:To demonstrate the suitability of the new rMSI technology for the detection of premalignant lesions and malignant BC in a preclinical mouse model using contrast agents.METHODS:Tumours were induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN), which is known to induce BC in rodent models. In total, 30 mice (C57BL/6) were fed with 0.1% BBN ad libitum in drinking water for up to 5 months. Bladders were excised at 3 (n = 6) and 5 months (n = 24) of treatment and incubated ex vivo with Hexaminolevulinat (HAL, Hexvix®), CD47-FITC, CD90.2-FITC or a combination of CD90.2-FITC/CD47-FITC and HAL. The bladders were analyzed by an endoscopic rMSI prototype system equipped with a spectral filter (Chroma), a 4 mm endoscope (Karl Storz) with 30° optic, a LED light source and a PC with a microcontroller board.RESULTS:5-month treatment of mice with 0.1% BBN led to the formation of squamous carcinoma (46%, n = 11) while urothelial carcinoma was observed only in one mouse (4%, n = 1). Carcinoma in situ (CIS) was detectable in twelve out of twenty-four mice (50%, n = 12) treated for 5 month and in three out of six mice (50%, n = 3) treated for 3 months.The metabolite of HAL, protoporphyrin IX (PpIX), could be reliably and specifically detected in all of mouse bladder tumours and CIS. However, detection of the CD90.2 surface marker was less reliable, potentially due to species- or tumour-subtype specificity.CONCLUSIONS:This model offers the potential for preclinical imaging studies with combined fluorescence targets, e.g. HAL, in combination with BC-specific antibodies.

Journal

Bladder Cancer – IOS Press

Published: Sep 21, 2020

References

  • Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
    Antoni
  • Assessment of costs associated with adverse events in patients with cancer
    Wong
  • EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013
    Babjuk
  • Current Disease Management of Primary Urethral Carcinoma
    Janisch
  • Novel endoscopic visualization techniques for bladder cancer detection: a review of the contemporary literature
    Mari
  • Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study
    Kriegmair
  • Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature
    Rink
  • Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis
    Zheng
  • Value of fluorescence cystoscopy in high risk non-muscle invasive bladder cancer
    Mayr
  • Spectral and temporal multiplexing for multispectral fluorescence and reflectance imaging using two color sensors
    Dimitriadis
  • Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging
    Kriegmair
  • Endoscopic molecular imaging of human bladder cancer using a CD47 antibody
    Pan
  • Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers
    Skowron
  • Three differentiation states risk-stratify bladder cancer into distinct subtypes
    Volkmer
  • Comparison of bladder tumors induced in rats and mice with N-butyl-N-(4-hydroxybutyl)-nitrosoamine
    Akagi
  • Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response
    Bertram
  • Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients
    Fantini
  • Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma
    Shin
  • Review: BBN as an urothelial carcinogen
    Vasconcelos-Nobrega
  • Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience
    Kennedy
  • Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study
    Lange
  • Protoporphyrin IX-accumulation in human tumor cells following topical ALA- and h-ALA-application in vivo
    Zenzen
  • Bladder cancers arise from distinct urothelial sub-populations
    Van Batavia